Defined immune dysregulation and COVID vaccination
Study code
NBR122
Lead researcher
Christine Parkinson
Study type
Samples and data
Institution or company
Cambridge University Hospitals
Researcher type
Academic
Speciality area
Infection, COVID
Summary
Currently it is unclear if at risk patient groups respond to COVID-19 vaccination, has adverse risk of toxicity or a blunting of vaccine efficacy. We are in a unique position to assess this as we will collect blood samples from a well defined cohort of subjects with an established diagnosis of a disease causing single gene defect that will be imminently offered the vaccine. We will compare this with immunotherapy treated patients. We will quantitatively measure adaptive immunity pre- and post- vaccination in these subjects and assess the correlation of this with either vaccine adverse effects or vaccine efficacy.